NCT03267433 2026-03-02
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
Clinical Trials
6 trialsNCT04166318 2026-03-02
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT06820957 2026-02-17
Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body
Children's Oncology Group
Phase 2/3 Active not recruiting
NCT04203316 2026-01-09
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
Children's Oncology Group
Phase 2 Active not recruiting
NCT02176967 2025-12-22
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
Children's Oncology Group
Phase 3 Active not recruiting
NCT04385277 2025-10-27
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 2 Active not recruiting